Microtubule destabilising agents: far more than just antimitotic anticancer drugs

Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105

(2016) Darcy Bates et al.   CANCER BIOLOGY & THERAPY

The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4

(2016) Min Su et al.   Scientific Reports

Death-associated protein kinase 2 mediates nocodazole-induced apoptosis through interaction with tubulin

(2015) Kinuka Isshiki et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Hitting the brakes: targeting microtubule motors in cancer

(2015) Gayathri Chandrasekaran et al.   BRITISH JOURNAL OF CANCER

Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemiain vivo

(2015) Darcy J. P. Bates et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Concise Guide to PHARMACOLOGY 2015/16: Overview

(2015) Stephen PH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

(2015) Stephen PH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent

(2015) N. F. Dybdal-Hargreaves et al.   CLINICAL CANCER RESEARCH

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Jean-Yves Blay et al.   LANCET ONCOLOGY

Control of microtubule organization and dynamics: two ends in the limelight

(2015) Anna Akhmanova et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

(2015) Christopher Southan et al.   NUCLEIC ACIDS RESEARCH

Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins

(2015) D. J. Colin et al.   Open Biology

Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function

(2014) Jessica J. Field et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Antibody–drug conjugates—A new wave of cancer drugs

(2014) Hervé Bouchard et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole

(2014) Federica Frezzato et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)

(2014) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane–platinum regimen as first-line therapy for metastatic non-small cell lung cancer

(2014) Joachim von Pawel et al.   LUNG CANCER

Targeting Microtubules by Natural Agents for Cancer Therapy

(2014) E. Mukhtar et al.   MOLECULAR CANCER THERAPEUTICS

Prometaphase arrest-dependent phosphorylation of Bcl-2 and Bim reduces the association of Bcl-2 with Bak or Bim, provoking Bak activation and mitochondrial apoptosis in nocodazole-treated Jurkat T cells

(2013) Cho Rong Han et al.   APOPTOSIS

Tubulin: an example of targeted chemotherapy

(2013) Jenny Seligmann et al.   Future Medicinal Chemistry

Vinblastine Rapidly Induces NOXA and Acutely Sensitizes Primary Chronic Lymphocytic Leukemia Cells to ABT-737

(2013) D. J. P. Bates et al.   MOLECULAR CANCER THERAPEUTICS

Eribulin: A Novel Cytotoxic Chemotherapy Agent

(2012) Jessica N Preston et al.   ANNALS OF PHARMACOTHERAPY

Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells

(2012) Wei-Hsin Chiu et al.   BIOCHEMICAL PHARMACOLOGY

Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine

(2012) Jeffrey A. Silverman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale

(2012) E. Komlodi-Pasztor et al.   CLINICAL CANCER RESEARCH

Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent

(2012) M Benezra et al.   LEUKEMIA

An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site

(2012) Yan Lu et al.   PHARMACEUTICAL RESEARCH

c-Jun N-terminal kinase mediates microtubule-depolymerizing agent-induced microtubule depolymerization and G2/M arrest in MCF-7 breast cancer cells

(2011) Juan Chen et al.   ANTI-CANCER DRUGS

Optimized anti-tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule

(2011) H. Ehrhardt et al.   BLOOD

Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis

(2011) Darcy J.P. Bates et al.   CANCER BIOLOGY & THERAPY

Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation

(2011) D. Rischin et al.   CLINICAL CANCER RESEARCH

Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic

(2011) Matthew A. Spear et al.   CURRENT DRUG TARGETS

Multiple BH3 Mimetics Antagonize Antiapoptotic MCL1 Protein by Inducing the Endoplasmic Reticulum Stress Response and Up-regulating BH3-only Protein NOXA

(2011) Tina C. Albershardt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties

(2011) Bernard L. Flynn et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of Chemosensitivity Nodes for Vinblastine through Small Interfering RNA High-Throughput Screens

(2011) C. A. Kitchens et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The proliferation rate paradox in antimitotic chemotherapy

(2011) Timothy J. Mitchison   MOLECULAR BIOLOGY OF THE CELL

Too early to say, “no targeting of mitosis!”

(2011) Katsumi Kitagawa   Nature Reviews Clinical Oncology

Mitosis is not a key target of microtubule agents in patient tumors

(2011) Edina Komlodi-Pasztor et al.   Nature Reviews Clinical Oncology

Microtubule targeting agents: from biophysics to proteomics

(2010) D. Calligaris et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The Vascular Targeting Agent Combretastatin-A4 and a Novel cis-Restricted  -Lactam Analogue, CA-432, Induce Apoptosis in Human Chronic Myeloid Leukemia Cells and Ex Vivo Patient Samples Including Those Displaying Multidrug Resistance

(2010) L. M. Greene et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy

(2010) G. Kremmidiotis et al.   MOLECULAR CANCER THERAPEUTICS

Vinblastine Induces Acute, Cell Cycle Phase–Independent Apoptosis in Some Leukemias and Lymphomas and Can Induce Acute Apoptosis in Others when Mcl-1 Is Suppressed

(2010) Bethany L. Salerni et al.   MOLECULAR CANCER THERAPEUTICS

A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents

(2009) Peace Mabeta et al.   ANGIOGENESIS

Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells

(2009) Bi-ke Zhu et al.   ANTI-CANCER DRUGS

Antivascular Actions of Microtubule-Binding Drugs

(2009) E. L. Schwartz   CLINICAL CANCER RESEARCH

Kinesin-1 Regulates Microtubule Dynamics via a c-Jun N-terminal Kinase-dependent Mechanism

(2009) Vanessa Daire et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers

(2009) Chun Hei Antonio Cheung et al.   Molecular Cancer

Cancer Cells Display Profound Intra- and Interline Variation following Prolonged Exposure to Antimitotic Drugs

(2008) Karen E. Gascoigne et al.   CANCER CELL

Death through a tragedy: mitotic catastrophe

(2008) H Vakifahmetoglu et al.   CELL DEATH AND DIFFERENTIATION

Distinct signaling pathways of microtubule inhibitors - vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively

(2008) Sergey N. Kolomeichuk et al.   FEBS Journal

Key role for Bak activation and Bak-Bax interaction in the apoptotic response to vinblastine

(2008) M. Upreti et al.   MOLECULAR CANCER THERAPEUTICS

Multisite Phosphorylation Regulates Bim Stability and Apoptotic Activity

(2008) Anette Hübner et al.   MOLECULAR CELL

Potential Mechanisms of Resistance to Microtubule Inhibitors

(2008) Maria Kavallaris et al.   SEMINARS IN ONCOLOGY

The contribution of c-Jun N-terminal kinase activation and subsequent Bcl-2 phosphorylation to apoptosis induction in human B-cells is dependent on the mode of action of specific stresses

(2008) Donna E. Muscarella et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY